The EGFR vIII mutation has been observed in approximately 40% of SCCHN patients, associated with chemotherapy resistance and decreased growth inhibition in response to Cetuximab [52]–[54]. This evidence concerns the gene COX8A and head and neck squamous cell carcinoma.